| 3.56 0.03 (0.85%) | 12-22 00:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.95 |
1-year : | 5.78 |
| Resists | First : | 4.23 |
Second : | 4.95 |
| Pivot price | 3.91 | |||
| Supports | First : | 3.81 |
Second : | 3.54 |
| MAs | MA(5) : | 3.92  |
MA(20) : | 3.91 |
| MA(100) : | 4.56 |
MA(250) : | 3.92 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.9 |
D(3) : | 42.5 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 7.26 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AIKI ] has closed above bottom band by 47.4%. Bollinger Bands are 60.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.92 - 3.95 | 3.95 - 3.97 |
| Low: | 3.7 - 3.72 | 3.72 - 3.75 |
| Close: | 3.86 - 3.9 | 3.9 - 3.94 |
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Thu, 22 Dec 2022
AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH) - PR Newswire
Mon, 28 Nov 2022
AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes - PR Newswire
Sun, 12 Jun 2022
AIkido Pharma Appoints Soo Yu Director - citybiz
Fri, 03 Jun 2022
AIkido Announces Reverse Stock Split - PR Newswire
Thu, 12 May 2022
AIkido Pharma Secures Interest in Databricks Inc. - PR Newswire
Thu, 11 Nov 2021
AIkido Pharma Announces Third Quarter Highlights and Corporate Update - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 13.2 (%) |
| Held by Institutions | 10.8 (%) |
| Shares Short | 70 (K) |
| Shares Short P.Month | 75 (K) |
| EPS | -1.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -9.2 % |
| Return on Equity (ttm) | -18.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -2.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.99 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 25.6% |
| Dividend Pay Date | 2019-05-09 |
| Ex-Dividend Date | 1980-05-11 |
|
|
|
|
|
|
|
|
|